1-(tert-butyl)3-methyl-piperazine | 1368699-97-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-(tert-butyl)3-methyl-piperazine
• 英文别名: tert-butyl-3-methylpiperazine；1-Tert-butyl-3-methylpiperazine
• CAS: 1368699-97-1
• 化学式: C₉H₂₀N₂
• 分子量: 156.271
• InChiKey: PGEJXJAICLMXCF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(tert-butyl)3-methyl-piperazine 、 对甲苯磺酰氯 在 咪唑 、 三乙胺 作用下， 生成
  参考文献：
  名称：

  Dynamic thermodynamic resolution of lithiated N-Boc-N′-alkylpiperazines

  摘要：

  Deprotonation of N-Boc-N'-alkylpiperazines with sec-BuLi in Et(2)O-TMEDA gave the 2-lithio derivatives which were resolved in the presence of a chiral ligand. The best ligands for the asymmetric substitution were diamino-alkoxides that promoted a dynamic thermodynamic resolution (DTR) of the organolithium at -30 degrees C. Electrophilic quench gave enantiomerically enriched 2-substituted piperazines. Of a selection of piperazines, the N'-t-butyl derivative gave the best results, with the product N-Boc-N'-t-butyl-2-substituted piperazines being formed with enantiomer ratios up to 81:19. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2010.05.019
• 作为产物：
  描述：

  Tert-butyl 4-tert-butyl-2-methylpiperazine-1-carboxylate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 1-(tert-butyl)3-methyl-piperazine
  参考文献：
  名称：

  Dynamic thermodynamic resolution of lithiated N-Boc-N′-alkylpiperazines

  摘要：

  Deprotonation of N-Boc-N'-alkylpiperazines with sec-BuLi in Et(2)O-TMEDA gave the 2-lithio derivatives which were resolved in the presence of a chiral ligand. The best ligands for the asymmetric substitution were diamino-alkoxides that promoted a dynamic thermodynamic resolution (DTR) of the organolithium at -30 degrees C. Electrophilic quench gave enantiomerically enriched 2-substituted piperazines. Of a selection of piperazines, the N'-t-butyl derivative gave the best results, with the product N-Boc-N'-t-butyl-2-substituted piperazines being formed with enantiomer ratios up to 81:19. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2010.05.019

文献信息

• Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20150231142A1

  公开（公告）日：2015-08-20

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及含有上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES
  申请人：GRUNENTHAL GMBH

  公开号：US20140066426A1

  公开（公告）日：2014-03-06

  The invention relates to pyrrole carboxamides bearing a fluoromethyl-moiety as voltage gated calcium channel blockers, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

  这项发明涉及带有氟甲基基团的吡咯酮羧酰胺作为电压门控钙通道阻滞剂，以及含有这些化合物的药物组合物，还涉及这些化合物用于治疗和/或预防疼痛以及其他疾病和/或紊乱。
• [EN] TETRAHYDROQUINAZOLINONE DERIVATIVES AS PARP INHIBITORS<br/>[FR] DÉRIVÉS TÉTRAHYDROQUINAZOLINONE UTILISÉS COMME INHIBITEURS DE PARP
  申请人：LUPIN LTD

  公开号：WO2014009872A1

  公开（公告）日：2014-01-16

  Disclosed are compounds of formula (I), their tautomeric forms, stereoisomers, and pharmaceutically acceptable salts thereof, wherein R1-R6, R7a-d, R8a-d, A, M, n, and p are as defined in the specification, pharmaceutical compositions including a compound, tautomer, stereoisomer, or salt thereof, and methods of treating or preventing diseases or disorders, for example, cancer, that are amenable to treatment or prevention by inhibiting the PARP enzyme of a subject.

  公开的是式(I)的化合物，它们的互变异构体、立体异构体和药学上可接受的盐，其中R1-R6、R7a-d、R8a-d、A、M、n和p如规范中所定义，包括一种化合物、互变异构体、立体异构体或其盐的药物组合物，以及治疗或预防疾病或疾病的方法，例如癌症，通过抑制受试者的PARP酶可治疗或预防的疾病。
• NOVEL INDENO[1,2-c]QUINOLIN-11-ONE DERIVATIVES, PREPARATION METHOD AND APPLICATION THEREOF
  申请人：National Defense Medical Center

  公开号：US20150197492A1

  公开（公告）日：2015-07-16

  The present invention provides a novel series of indeno[1,2-c]quinolin-11-one derivatives and further provides their preparation methods as well as applications. Said applications includes utilizing such derivatives as pharmaceutical compositions for treating cancers; moreover, said applications includes the capability possessed by such derivatives to effectively inhibit cancer cell growth as well as the activity of Type I topoisomerases and can be further applied for cancer treatment.

  本发明提供了一系列新颖的indeno[1,2-c]quinolin-11-one衍生物，并进一步提供其制备方法以及应用。所述应用包括将这些衍生物用作治疗癌症的药物组合物；此外，所述应用包括这些衍生物具有有效抑制癌细胞生长以及抑制Ⅰ型拓扑异构酶活性的能力，并可进一步应用于癌症治疗。
• PYRIDYL-THIAZOLYL INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION
  申请人：ZHANG Yan

  公开号：US20120129843A1

  公开（公告）日：2012-05-24

  This invention relates to thiazole I and its therapeutic and prophylactic uses, wherein the variables R z , Q, J, R 1 , R 3 , R 5 , and R 6 are defined in the specification. Disorders treated and/or prevented include rheumatoid arthritis.

  这项发明涉及噻唑I及其治疗和预防用途，其中变量Rz、Q、J、R1、R3、R5和R6在规范中有定义。治疗和/或预防的疾病包括类风湿关节炎。